U.S. ATryn Development Timeline for HD Indication [Based on the guidance from the BIO webcast this week.] 4Q07: Complete study; report top-line results; begin “rolling” BLA submission. 1Q08: Report antibody data; complete data analysis. Mid 2008: Submit final module of BLA. Late 2008/early 2009: FDA decision on BLA (assuming a six-month priority review).